Antipsychotic medications are the most common cause of akathisia, but they aren’t the only ones. Antidepressants, anti-nausea drugs, and several other medication classes can trigger this distressing side effect, which creates an overwhelming urge to move and a deep sense of inner restlessness. Roughly one in four people taking older antipsychotics will experience it, and newer antipsychotics carry similar risk.
Antipsychotic Medications
Antipsychotics are the drug class most strongly linked to akathisia. These medications work by blocking dopamine receptors in the brain, and that same mechanism is what produces the restlessness. High-potency older antipsychotics (first-generation drugs like haloperidol and fluphenazine) carry the greatest risk, especially at high doses or when the dose is increased quickly. Lower-potency options like chlorpromazine are less likely to trigger it.
Newer antipsychotics (second-generation drugs like risperidone, aripiprazole, olanzapine, quetiapine, and ziprasidone) were once thought to be much safer in this regard. Data from the large CATIE trial, which tracked people with schizophrenia over 12 months, tells a more nuanced story. The covariate-adjusted akathisia rate was 26 to 35% for the newer antipsychotics and 35% for the intermediate-potency older drug perphenazine. That’s a smaller gap than many clinicians expected. Among the newer drugs, quetiapine tends to have the lowest akathisia potential, while aripiprazole and risperidone are more frequently implicated.
Antidepressants
SSRIs and SNRIs, the most commonly prescribed antidepressants, can also cause akathisia. The risk is lower than with antipsychotics, but it catches many people off guard because these medications aren’t typically associated with movement-related side effects. SSRIs like fluoxetine, sertraline, paroxetine, and escitalopram have all been reported to trigger it. Among SNRIs, venlafaxine and duloxetine are the most frequently cited.
Antidepressant-induced akathisia tends to appear within the first few weeks of starting the medication or after a dose increase, mimicking the timeline of antipsychotic-induced cases. It’s sometimes misinterpreted as worsening anxiety or agitation, which can lead a prescriber to raise the dose rather than recognize the side effect. This distinction matters because increasing the dose of the drug causing akathisia will make it worse.
Anti-Nausea and GI Medications
Several drugs used to treat nausea and digestive problems work by blocking the same dopamine receptors that antipsychotics target. Metoclopramide, commonly prescribed for gastroparesis and nausea, is one of the most well-known non-psychiatric causes of akathisia. Prochlorperazine, used for severe nausea and vertigo, is another. These medications are technically dopamine antagonists, which places them in the same pharmacological family as antipsychotics even though they’re prescribed for completely different reasons.
People sometimes encounter these drugs in emergency rooms or surgical recovery settings, where they’re given for post-operative nausea. Because the prescriber and the patient may not be thinking about movement side effects in that context, akathisia from anti-nausea drugs often goes unrecognized.
Other Medications Linked to Akathisia
Beyond the major categories above, several less obvious medications have been associated with akathisia:
- Calcium channel blockers: Cinnarizine and flunarizine, used for vertigo and migraines in some countries, have dopamine-blocking properties that can produce akathisia.
- Lithium: Used as a mood stabilizer in bipolar disorder, lithium has been reported to cause akathisia in some patients.
- Buspirone: An anti-anxiety medication that affects serotonin signaling, occasionally linked to restlessness resembling akathisia.
- Stimulants and pre-surgical sedatives: Isolated cases have been reported with a range of other drug classes, though these are far less common than antipsychotic or antidepressant-related cases.
Why These Medications Cause It
The core mechanism behind akathisia involves blocking dopamine receptors, particularly in an area of the brainstem that regulates alertness and motor activity. When these receptors are blocked, it triggers a cascade: the brain’s norepinephrine (adrenaline-related) signaling ramps up, calming circuits that rely on GABA become less active, and acetylcholine release increases in movement-related brain regions. The result is a mismatch between the brain’s motor planning circuits and its reward system. Your body generates purposeless, restless movements and an inner drive to keep moving that feels impossible to suppress.
This is why high-potency dopamine-blocking drugs carry the greatest risk. The tighter a medication binds to dopamine receptors and the more receptors it occupies, the more likely it is to set off this chain reaction. It also explains why the condition can feel so different from ordinary restlessness or anxiety. It’s not psychological worry driving the movement. It’s a neurochemical imbalance in the circuits that connect sensation, movement, and reward.
When Symptoms Typically Appear
Akathisia doesn’t follow a single timeline. Acute akathisia, the most common form, develops within days to a few weeks of starting a new medication or increasing a dose. It’s characterized by intense inner restlessness and an urgent need to pace, shift weight, or rock. This form usually resolves if the medication is reduced or changed, and it generally lasts less than six months.
Tardive akathisia has a delayed onset, typically appearing more than three months after starting a medication or changing the dose. It’s often harder to treat and may persist even after the medication is stopped. This form is sometimes seen alongside other tardive movement disorders.
There’s also withdrawal akathisia, which can emerge when a medication is reduced or discontinued. This is particularly tricky because the natural instinct during a medication taper is to assume that new symptoms reflect the return of the underlying condition rather than a withdrawal effect.
What Raises Your Risk
Not everyone on a dopamine-blocking medication develops akathisia, and several factors influence who does. High doses and rapid dose increases are the strongest predictors. Starting a medication at a high dose or escalating quickly gives the brain less time to adapt. Switching from a lower-potency medication to a higher-potency one carries similar risk.
Iron deficiency appears to play a role as well. Iron is involved in dopamine production and receptor function, and people with low iron levels seem more vulnerable to akathisia, a connection that also shows up in restless legs syndrome. Age may factor in too, with some evidence suggesting middle-aged adults are at higher risk than younger or older patients, though akathisia can occur at any age.
How Akathisia Feels
The hallmark of akathisia is a combination of inner restlessness and visible movement. People describe it as a crawling sensation under the skin, an inability to feel comfortable in any position, or a relentless urge to get up and walk. It’s not the same as feeling anxious or fidgety. The distress is physical and immediate, often described as one of the most unpleasant side effects a person can experience from a psychiatric medication.
Objectively, it shows up as rocking while standing, crossing and uncrossing legs repeatedly, pacing, or an inability to sit still for more than a few minutes. The subjective experience, that feeling of internal agitation and discomfort, can be present even when the visible movements are subtle. Clinicians assess severity using the Barnes Akathisia Rating Scale, a four-item tool that scores both the observable restlessness and the person’s own report of inner distress on a scale from 0 to 3.
How It’s Managed
The first and most effective step is adjusting the medication causing the problem. This might mean lowering the dose, slowing the rate of dose increase, or switching to a medication with a lower akathisia risk (quetiapine is a common switch target among antipsychotics, and chlorpromazine among older drugs). For many people, these changes alone resolve symptoms.
When the offending medication can’t be changed, because it’s controlling psychosis or another serious condition effectively, add-on treatments can help. Beta-blockers are considered the first-line add-on, with propranolol being the most studied. Some clinicians also use certain antihistamines or benzodiazepines for short-term relief, though these come with their own side effect profiles. The key is recognizing akathisia early, because the longer it persists untreated, the harder it can be to resolve, and the more likely a person is to stop their medication entirely.